Literature DB >> 34716726

Evidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis.

Adrian Tira1, Lela Buckingham1.   

Abstract

Glioblastoma (GBM) is a highly malignant primary brain tumour displaying rapid cell proliferation and infiltration. GBM primarily occurs at older age; however, younger populations have also been affected. In GBM and other cancers, genetic and epigenetic alterations promote tumorigenesis causing increased cell proliferation and invasiveness. This investigation explored epigenetic events as contributing factors, especially in gliomas that arise in patients aged 40-60 years. Furthermore, DNA damage in tumours with respect to age was assessed. Archival fixed tissues from 88 cases of glioblastoma and adjacent non-malignant tissues were tested. Global methylation and DNA damage were measured using ELISA detection of 5-methyl cytosine and 8-hydroxy guanine, respectively. IDH mutations and CDKN2 promoter hypermethylation were analysed by pyrosequencing. Tumour tissue was hypomethylated compared with non-malignant tissue (P = .001), and there was a trend towards increased methylation with increasing age. There was a significant increase in DNA damage in patients older than forty years compared with those aged forty years or younger (P = .035). CDKN2 promoter methylation levels followed the age trends of global methylation in this patient group. Patients younger than 60 had more frequently mutated IDH (P = .004). Conclusions: The data support the potential of epigenetic factors in promoting tumorigenesis in younger patients, while increased DNA damage contributes to tumorigenesis in the older patients.
© 2021 Company of the International Journal of Experimental Pathology (CIJEP).

Entities:  

Keywords:  Brain cancer; DNA injury; epigenetics; methylation

Mesh:

Substances:

Year:  2021        PMID: 34716726      PMCID: PMC8626623          DOI: 10.1111/iep.12402

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  36 in total

Review 1.  Brain Tumors of Glial Origin.

Authors:  Christopher A Waker; Robert M Lober
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

Review 3.  Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.

Authors:  M A Qazi; P Vora; C Venugopal; S S Sidhu; J Moffat; C Swanton; S K Singh
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 4.  Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes.

Authors:  Aurélie Van Tongelen; Axelle Loriot; Charles De Smet
Journal:  Cancer Lett       Date:  2017-03-22       Impact factor: 8.679

5.  CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.

Authors:  M K Sibin; Dhananjaya I Bhat; K V L Narasingarao; Ch Lavanya; G K Chetan
Journal:  Tumour Biol       Date:  2015-04-29

Review 6.  DNA repair mechanisms and their clinical impact in glioblastoma.

Authors:  Hélène Erasimus; Matthieu Gobin; Simone Niclou; Eric Van Dyck
Journal:  Mutat Res Rev Mutat Res       Date:  2016-06-21       Impact factor: 5.657

7.  CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.

Authors:  Dawn P Bradly; Paolo Gattuso; Mark Pool; Sanjib Basu; Michael Liptay; Philip Bonomi; Lela Buckingham
Journal:  Diagn Mol Pathol       Date:  2012-12

Review 8.  Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.

Authors:  Laura Annovazzi; Marta Mellai; Davide Schiffer
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

Review 9.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

10.  Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.

Authors:  Yasuo Iwadate; Natsuki Shinozaki; Tomoo Matsutani; Yoshio Uchino; Naokatsu Saeki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-02-04       Impact factor: 10.154

View more
  1 in total

1.  Evidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis.

Authors:  Adrian Tira; Lela Buckingham
Journal:  Int J Exp Pathol       Date:  2021-10-30       Impact factor: 1.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.